Dr. van den Bent on INTELLANCE 2 Trial for Recurrent Glioblastoma

Video

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the INTELLANCE 2 trial for recurrent glioblastoma.

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the INTELLANCE 2 trial for recurrent glioblastoma. He presented updated data at the 2018 ASCO Annual Meeting.

About 50% of glioblastoma cases are characterized by EGFR mutations, but recent trials with EGFR inhibitors have not worked. Since the introduction of radiotherapy combined with temozolomide (Temodal) as the standard of care, physicians have not made any progress, says van den Bent. INTELLANCE 2, a randomized phase II trial, tests the antibody-drug conjugate depatux-m alone, depatuxizumab mafodotin (depatux-m) with temozolomide, and a control arm of either temozolomide or lomustine (Gleostine) alone.

After a 1-year follow-up, the combination of depatux-m and temozolomide resulted in a median 1-year overall survival rate of 40%, compared with 28% in the control arm. Patients on the combination arm were treated with depatux-m 1 mg/kg every 2 weeks and temozolomide 150 mg-200 mg/kg2 days 1 to 5 every 4 weeks.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute